0001415889-23-013473.txt : 20230921
0001415889-23-013473.hdr.sgml : 20230921
20230921165034
ACCESSION NUMBER: 0001415889-23-013473
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230921
FILED AS OF DATE: 20230921
DATE AS OF CHANGE: 20230921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferguson Matthew
CENTRAL INDEX KEY: 0001304079
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39577
FILM NUMBER: 231269582
MAIL ADDRESS:
STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC.
STREET 2: 740 BAY ROAD
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ELUTIA INC.
CENTRAL INDEX KEY: 0001708527
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 474790334
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12510 PROSPERITY DRIVE
STREET 2: SUITE 370
CITY: SILVER SPRING
STATE: MD
ZIP: 20904
BUSINESS PHONE: 240-247-1143
MAIL ADDRESS:
STREET 1: 12510 PROSPERITY DRIVE
STREET 2: SUITE 370
CITY: SILVER SPRING
STATE: MD
ZIP: 20904
FORMER COMPANY:
FORMER CONFORMED NAME: AZIYO BIOLOGICS, INC.
DATE OF NAME CHANGE: 20170605
4
1
form4-09212023_080929.xml
X0508
4
2023-09-21
0001708527
ELUTIA INC.
ELUT
0001304079
Ferguson Matthew
C/O ELUTIA INC.
12510 PROSPERITY DRIVE, SUITE 370
SILVER SPRING
MD
20904
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Class A Common Stock
2023-09-21
4
A
0
70053
A
120519
D
Warrants (rights to buy)
1.4275
2023-09-21
4
A
0
105080
A
2023-09-21
Class A Common Stock
105080
105080
D
The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock.
Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.
/s/ Jeffrey Hamet, Attorney-in-Fact for Matthew Ferguson
2023-09-21